COMMUNIQUÉS West-GlobeNewswire

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2025 Financial Results
14/11/2025
Day One Biopharmaceuticals, Inc. to Acquire Mersana Therapeutics, Inc. Agreement provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate [...]
Teleflex to Present at the Jefferies Global Healthcare Conference in London
14/11/2025
WAYNE, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX) is scheduled to speak at the Jefferies Global Healthcare Conference in London on Tuesday, November 18, 2025, at 10:00 a.m. ( [...]
Orion receives award for international growth from the President of the Republic of Finland
14/11/2025
ORION CORPORATION PRESS RELEASE 14 NOVEMBER 2025 at 13.30 EET Orion receives award for international growth from the President of the Republic of Finland Today, the President of the Republic of Finland, Alexander Stubb [...]
Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
14/11/2025
Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes Recommendation based on the TN-10 study, demonstrating Teizeild’s ability to delay the onset of stage 3 type 1 diabetes [...]
Communiqué de presse : Teizeild, un médicament Sanofi, a reçu l’approbation du CHMP pour une autorisation de mise sur le marché dans l’UE chez les patients atteints de diabète de type 1 de stade 2
14/11/2025
Teizeild, un médicament Sanofi, a reçu l’approbation du CHMP pour une autorisation de mise sur le marché dans l’UE chez les patients atteints de diabète de type 1 de stade 2 La recommandation s’appuie sur l’étude TN-10 [...]
New study finds half of young men at risk of problem anger
14/11/2025
VANCOUVER, British Columbia, Nov. 14, 2025 (GLOBE NEWSWIRE) -- New research from the Canadian Men’s Health Foundation (CMHF) reveals half of Canadian men aged 19–29 are at risk of problem anger—when anger interferes [...]
Avadel Receives Unsolicited Proposal from Lundbeck
14/11/2025
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION [...]
Bioxodes presents BIOX-101 clinical data showing breakthrough potential for stroke in webcast with Prof Dr Robin Lemmens
14/11/2025
Prof Lemmens underscores large unmet medical need in intracerebral hemorrhage “Very encouraging” data from Phase 2a trial with lead asset BIOX-101 Bioxodes is preparing for a possibly registrational Phase 2b trial, [...]
Voting Rights and Shares Capital of the Company
14/11/2025
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Nov. 14, 2025 (GLOBE NEWSWIRE [...]
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
14/11/2025
Conformément aux articles L.233-8 II du Code de commerce et 223-16 du Règlement Général de l’Autorité des Marchés Financiers PARIS, 14 nov. 2025 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Paris / Nasdaq Euronext [...]
Nyxoah Obtient des Engagements de Financement pouvant atteindre U.S. $77 Millions pour Supporter la Commercialisation de Genio aux États-Unis
14/11/2025
INFORMATIONS PRIVILÉGIÉES INFORMATIONS RÉGLEMENTÉES Nyxoah Obtient des Engagements de Financement pouvant atteindre U.S. $77 Millions pour Supporter la Commercialisation de Genio aux États-Unis Les financements [...]
Bavarian Nordic Announces Interim Results for the First Nine Months of 2025
14/11/2025
COPENHAGEN, Denmark, November 14, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today its interim financial results for the first nine months of 2025 and business progress for the third quarter of 2025. Revenue for [...]
Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada
14/11/2025
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to [...]
Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares
14/11/2025
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its [...]
Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs
14/11/2025
Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) is issuing the following clarification regarding its press release issued earlier this morning [...]
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio
14/11/2025
INSIDE INFORMATION REGULATED INFORMATION Correction and Replacement Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Financings are comprised of equity investments [...]
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Approved in the United Kingdom
14/11/2025
TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: [...]
Novo Nordisk A/S: Candidate for the Board of Directors will not seek election
13/11/2025
Bagsværd, Denmark, 13 November 2025 – Today, it was announced that Mikael Dolsten will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025, as otherwise [...]
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026
13/11/2025
New NIAID Non-Dilutive Funding Award of up to US $40Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs LIKMEZ® (ATI-1501): Building Commercial Momentum in the U.S. Through Re- [...]

Pages